ACADIA Pharmaceuticals Inc (NASDAQ:ACAD)
| 27.20 Data as of Mar 07 |  +0.03 / +0.11%Today’s Change | 6.04 Today|||52-Week Range 32.00 | +8.84% Year-to-Date |
Latest ACAD News | Press Releases
| Morning Lowers for Mar. 5, 2014: XOMA, USU, CSIQ, AUDC, RATE Mar 05 / Benzinga | Acadia Pharmaceuticals: Here's What You Should Know About Its Surging Shares Feb 26 / MotleyFool.com |
| Today's Perilous Reversal Stock: ACADIA Pharmaceuticals (ACAD) Mar 05 / TheStreet.com | ACADIA Pharmaceuticals (ACAD) Jumps: Stock Rises 17.3% - Tale of the Tape Feb 24 / Zacks.com |
| ACADIA Pharmaceuticals Announces $150M Proposed Public Offering of Common Stock Mar 03 / Benzinga |
Today’s Trading
| Previous close | 27.17 |
| Today’s open | 27.84 |
| Day’s range | 26.71 - 28.32 |
| Volume | 2,962,822 |
| Average volume (3 months) | 1,664,091 |
| Market cap | $2.7B |
| Dividend yield | -- |
Data as of 4:00pm ET, 03/07/2014
Growth & Valuation
| Earnings growth (last year) | -15.79% |
| Earnings growth (this year) | -28.03% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -76.67% |
| P/E ratio | NM |
| Price/Sales | 1,870.76 |
| Price/Book | -- |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| WXWuXi Pharmatech (Cay... | 0.00 | 0.00% |
| MYGNMyriad Genetics Inc | +0.77 | +2.06% |
| ---- | ||
| CLVSClovis Oncology Inc | -1.57 | -1.84% |
Data as of 3:59pm ET, 03/07/2014
Financials
| Next reporting date | May 6, 2014 |
| EPS forecast (this quarter) | -$0.13 |
| Annual revenue (last year) | $1.1M |
| Annual profit (last year) | -$37.9M |
| Net profit margin | -3,314.24% |
Profile
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Uli Hacksell |
Treasurer, Chief Financial & Business Officer Thomas H. Aasen |
Corporate headquarters San Diego, California |
Forecasts
